Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

NEWARK, CA /ACCESS Newswire/ May 28, 2026 /Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026.

Format: Fireside Chat

Day/Time: Wednesday, June 3 at 9:55 A.M. ET

Webcast:https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPxxrEhwVAR5

Format: Fireside Chat

Day/Time: Wednesday, June 10 at 9:20 A.M. ET

Webcast:https://event.webcasts.com/starthere.jsp?ei=1764366&tp_key=bf1c052870&tp_special=8

If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.

A replay of the presentations will be available on the Company'sInvestor Relations Events and Presentationswebpage for one year following the event.

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™(icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website athttps://www.protagonist-inc.com.